

REFERENCES

- Aaronson, D. S. (2002). A Road Map for Those Who Don't Know JAK-STAT. *Science*, *296*(5573), 1653–1655. <https://doi.org/10.1126/science.1071545>
- Annunziato, A. T. (2008). DNA Packaging: Nucleosomes and Chromatin. *Nature Education*, *1*(1), 26.
- Barnes, C. J., & Kumar, R. (2004). Biology of the epidermal growth factor receptor family. *Cancer Treatment and Research*, *119*, 1–13.
- Bazley, L. A., & Gullick, W. J. (2005). The epidermal growth factor receptor family. *Endocrine-Related Cancer*, *12*(Supplement_1), S17–S27. <https://doi.org/10.1677/erc.1.01032>
- Blackadar, C. B. (2016). Historical review of the causes of cancer. *World Journal of Clinical Oncology*, *7*(1), 54. <https://doi.org/10.5306/wjco.v7.i1.54>
- Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997). CELLULAR RESPONSES TO INTERFERON- γ . *Annual Review of Immunology*, *15*(1), 749–795. <https://doi.org/10.1146/annurev.immunol.15.1.749>
- Cao, R., & Zhang, Y. (2004). The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. *Current Opinion in Genetics & Development*, *14*(2), 155–164. <https://doi.org/10.1016/j.gde.2004.02.001>
- Chen, D. S., & Mellman, I. (2013). Oncology Meets Immunology: The Cancer-Immunity Cycle. *Immunity*, *39*(1), 1–10. <https://doi.org/10.1016/j.immuni.2013.07.012>
- Cogle, C. R., Scott, B. L., Boyd, T., & Garcia-Manero, G. (2015). Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia. *The Oncologist*, *20*(12), 1404–1412. <https://doi.org/10.1634/theoncologist.2015-0165>
- Creighton, C. (2012). The molecular profile of luminal B breast cancer. *Biologics: Targets and Therapy*, *289*. <https://doi.org/10.2147/BTT.S29923>

- Dighe, A. S., Richards, E., Old, L. J., & Schreiber, R. D. (1994). Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN γ receptors. *Immunity*, *1*(6), 447–456.
[https://doi.org/10.1016/1074-7613\(94\)90087-6](https://doi.org/10.1016/1074-7613(94)90087-6)
- Ellis, H., & Mahadevan, V. (2013). Anatomy and physiology of the breast. *Surgery (Oxford)*, *31*(1), 11–14.
<https://doi.org/10.1016/j.mpsur.2012.10.018>
- Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017). Epigenetic plasticity and the hallmarks of cancer. *Science*, *357*(6348), eaal2380. <https://doi.org/10.1126/science.aal2380>
- Gabos, Z., Sinha, R., Hanson, J., Chauhan, N., Hugh, J., Mackey, J. R., & Abdulkarim, B. (2006). Prognostic Significance of Human Epidermal Growth Factor Receptor Positivity for the Development of Brain Metastasis After Newly Diagnosed Breast Cancer. *Journal of Clinical Oncology*, *24*(36), 5658–5663. <https://doi.org/10.1200/JCO.2006.07.0250>
- Goh, K. C. (1999). p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. *The EMBO Journal*, *18*(20), 5601–5608.
<https://doi.org/10.1093/emboj/18.20.5601>
- Guarneri, V., & Conte, P. (2009). Metastatic Breast Cancer: Therapeutic Options According to Molecular Subtypes and Prior Adjuvant Therapy. *The Oncologist*, *14*(7), 645–656.
<https://doi.org/10.1634/theoncologist.2009-0078>
- Gutierrez, C., & Schiff, R. (2011). HER2: Biology, detection, and clinical implications. *Archives of Pathology & Laboratory Medicine*, *135*(1), 55–62. <https://doi.org/10.1043/2010-0454-RAR.1>
- Hassiotou, F., & Geddes, D. (2013). Anatomy of the human mammary gland: Current status of knowledge. *Clinical Anatomy*, *26*(1), 29–48. <https://doi.org/10.1002/ca.22165>
- Higginson, J., Muir, C., & Munoz, M. (1992). Introduction to epidemiology. In: Human Cancer: Epidemiology and Environmental Causes. *Cambridge University Press*, 17–25.

- Holliday, D. L., & Speirs, V. (2011). Choosing the right cell line for breast cancer research. *Breast Cancer Research, 13*(4). <https://doi.org/10.1186/bcr2889>
- Hu, Z., Fan, C., Oh, D. S., Marron, J., He, X., Qaqish, B. F., ... Perou, C. M. (2006). [No title found]. *BMC Genomics, 7*(1), 96. <https://doi.org/10.1186/1471-2164-7-96>
- International Agency of Research on Cancer. (2018, September 12). Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018 [Press release].
- Kaminskas, E. (2005). FDA Drug Approval Summary: Azacitidine (5-azacytidine, Vidaza™) for Injectable Suspension. *The Oncologist, 10*(3), 176–182. <https://doi.org/10.1634/theoncologist.10-3-176>
- Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., ... Gelmon, K. (2010). Metastatic Behavior of Breast Cancer Subtypes. *Journal of Clinical Oncology, 28*(20), 3271–3277. <https://doi.org/10.1200/JCO.2009.25.9820>
- Kim, Y.-S., Hwan Do, J., Bae, S., Bae, D.-H., & Shick Ahn, W. (2010). Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma. *BMC Cancer, 10*(1). <https://doi.org/10.1186/1471-2407-10-576>
- Kochupurakkal, B. S., Wang, Z. C., Hua, T., Culhane, A. C., Rodig, S. J., Rajkovic-Molek, K., ... Iglehart, J. D. (2015). RelA-Induced Interferon Response Negatively Regulates Proliferation. *PLOS ONE, 10*(10), e0140243. <https://doi.org/10.1371/journal.pone.0140243>
- Kondo, Y., Shen, L., Cheng, A. S., Ahmed, S., Bumber, Y., Charo, C., ... Issa, J.-P. J. (2008). Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. *Nature Genetics, 40*(6), 741–750. <https://doi.org/10.1038/ng.159>
- Kosmidis, C., Sapalidis, K., Koletsas, T., Kosmidou, M., Efthimiadis, C., Anthimidis, G., ... Kesisoglou, I. (2018). Interferon- γ and Colorectal Cancer: An up-to date. *Journal of Cancer, 9*(2), 232–238. <https://doi.org/10.7150/jca.22962>

- Lacroix, M., Haibe-Kains, B., Hennuy, B., Laes, J., Lallemand, F., Gonze, I., ... Sotiriou, C. (2004). Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes. *Oncology Reports*.
<https://doi.org/10.3892/or.12.4.701>
- Lai, K.-C., Chang, K.-W., Liu, C.-J., Kao, S.-Y., & Lee, T.-C. (2008). IFN-Induced Protein with Tetratricopeptide Repeats 2 Inhibits Migration Activity and Increases Survival of Oral Squamous Cell Carcinoma. *Molecular Cancer Research*, 6(9), 1431–1439. <https://doi.org/10.1158/1541-7786.MCR-08-0141>
- Lee, J.-K., & Kim, K.-C. (2013). DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells. *Biochemical and Biophysical Research Communications*, 438(4), 647–652.
<https://doi.org/10.1016/j.bbrc.2013.07.128>
- Li, W., Wu, D., Niu, Z., Jiang, D., Ma, H., He, H., ... He, Y. (2016). 5-Azacytidine suppresses EC9706 cell proliferation and metastasis by upregulating the expression of SOX17 and CDH1. *International Journal of Molecular Medicine*, 38(4), 1047–1054. <https://doi.org/10.3892/ijmm.2016.2704>
- Lindner, D. J., Wu, Y., Haney, R., Jacobs, B. S., Fruehauf, J. P., Tuthill, R., & Borden, E. C. (2013). Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis. *Matrix Biology*, 32(2), 123–132.
<https://doi.org/10.1016/j.matbio.2012.11.010>
- Luque-Cabal, M., García-Tejido, P., Fernández-Pérez, Y., Sánchez-Lorenzo, L., & Palacio-Vázquez, I. (2016). Mechanisms behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It. *Clinical Medicine Insights: Oncology*, 10s1, CMO.S34537.
<https://doi.org/10.4137/CMO.S34537>

- Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., ... Haining, W. N. (2017). In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. *Nature*, 547(7664), 413–418. <https://doi.org/10.1038/nature23270>
- Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007). FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma. *The Oncologist*, 12(10), 1247–1252. <https://doi.org/10.1634/theoncologist.12-10-1247>
- Marieb, E. N., & Hoehn, K. (2019). *Human anatomy & physiology*.
- Miranda, T. B., Cortez, C. C., Yoo, C. B., Liang, G., Abe, M., Kelly, T. K., ... Jones, P. A. (2009). DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. *Molecular Cancer Therapeutics*, 8(6), 1579–1588. <https://doi.org/10.1158/1535-7163.MCT-09-0013>
- Miranda, T. B., & Jones, P. A. (2007). DNA methylation: The nuts and bolts of repression. *Journal of Cellular Physiology*, 213(2), 384–390. <https://doi.org/10.1002/jcp.21224>
- Moasser, M. M. (2007). The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis. *Oncogene*, 26(45), 6469–6487. <https://doi.org/10.1038/sj.onc.1210477>
- Nagai, Y., Tsuchiya, H., Ji, M. Q., Zhang, H., & Greene, M. I. (2017). Synergistic effect of IFN- γ on breast cancer targeted therapy. *The Journal of Immunology*, 198(1 Supplement), 141.14.
- Nanney, D. L. (1958). EPIGENETIC CONTROL SYSTEMS. *Proceedings of the National Academy of Sciences*, 44(7), 712–717. <https://doi.org/10.1073/pnas.44.7.712>
- National Institute of Health. (2019). 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors - Full Text View - ClinicalTrials.gov. Retrieved 20 March 2019, from <https://clinicaltrials.gov/ct2/show/NCT03366116>

- Nicole M Clarke, A. R. (2013). Genome-wide Identification of IRF1 Binding Sites Reveals Extensive Occupancy at Cell Death Associated Genes. *Journal of Carcinogenesis & Mutagenesis*.
<https://doi.org/10.4172/2157-2518.S6-009>
- Niess, H., Camaj, P., Mair, R., Renner, A., Zhao, Y., Jäckel, C., ... Bruns, C. J. (2015). Overexpression of IFN-induced protein with tetratricopeptide repeats 3 (IFIT3) in pancreatic cancer: Cellular “pseudoinflammation” contributing to an aggressive phenotype. *Oncotarget*, 6(5). <https://doi.org/10.18632/oncotarget.2494>
- Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., ... Botstein, D. (2000). Molecular portraits of human breast tumours. *Nature*, 406(6797), 747–752.
<https://doi.org/10.1038/35021093>
- Polyak, K., & Metzger Filho, O. (2012). SnapShot: Breast Cancer. *Cancer Cell*, 22(4), 562-562.e1.
<https://doi.org/10.1016/j.ccr.2012.06.021>
- Riaz, M., van Jaarsveld, M. T., Hollestelle, A., Prager-van der Smissen, W. J., Heine, A. A., Boersma, A. W., ... Martens, J. W. (2013). miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. *Breast Cancer Research*, 15(2).
<https://doi.org/10.1186/bcr3415>
- Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., ... Wolmark, N. (2005). Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. *New England Journal of Medicine*, 353(16), 1673–1684. <https://doi.org/10.1056/NEJMoa052122>
- Ross, J. S. (2003). The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy. *The Oncologist*, 8(4), 307–325. <https://doi.org/10.1634/theoncologist.8-4-307>
- Schoenborn, J. R., & Wilson, C. B. (2007). Regulation of Interferon- γ During Innate and Adaptive Immune Responses. In *Advances in Immunology* (Vol. 96, pp. 41–101). [https://doi.org/10.1016/S0065-2776\(07\)96002-2](https://doi.org/10.1016/S0065-2776(07)96002-2)

- Schwartz, J. L., Shajahan, A. N., & Clarke, R. (2011). The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer. *International Journal of Breast Cancer*, 2011, 1–9. <https://doi.org/10.4061/2011/912102>
- Sha, M., Mao, G., Wang, G., Chen, Y., Wu, X., & Wang, Z. (2015). DZNep inhibits the proliferation of colon cancer HCT116 cells by inducing senescence and apoptosis. *Acta Pharmaceutica Sinica B*, 5(3), 188–193. <https://doi.org/10.1016/j.apsb.2015.01.011>
- Shi, X.-Y., Ding, W., Li, T.-Q., Zhang, Y.-X., & Zhao, S.-C. (2017). Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway. *Medical Science Monitor*, 23, 5793–5802. <https://doi.org/10.12659/MSM.904597>
- Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., ... Crown, J. (2011). Adjuvant Trastuzumab in HER2-Positive Breast Cancer. *New England Journal of Medicine*, 365(14), 1273–1283. <https://doi.org/10.1056/NEJMoa0910383>
- Taniguchi, T., Ogasawara, K., Takaoka, A., & Tanaka, N. (2001). IRF Family of Transcription Factors as Regulators of Host Defense. *Annual Review of Immunology*, 19(1), 623–655. <https://doi.org/10.1146/annurev.immunol.19.1.623>
- Uddin, S., Majchrzak, B., Woodson, J., Arunkumar, P., Alsayed, Y., Pine, R., ... Platanias, L. C. (1999). Activation of the p38 Mitogen-activated Protein Kinase by Type I Interferons. *Journal of Biological Chemistry*, 274(42), 30127–30131. <https://doi.org/10.1074/jbc.274.42.30127>
- Uddin, S., Yenush, L., Sun, X.-J., Sweet, M. E., White, M. F., & Platanias, L. C. (1995). Interferon- α Engages the Insulin Receptor Substrate-1 to Associate with the Phosphatidylinositol 3'-Kinase. *Journal of Biological Chemistry*, 270(27), 15938–15941. <https://doi.org/10.1074/jbc.270.27.15938>

- Vahdat, L. T., Cohen, D. J., Zipin, D., Lo, K. S., Donovan, D., Savage, D., ... Hesdorffer, C. S. (2007). Randomized trial of low-dose interleukin-2 vs cyclosporine A and interferon- γ after high-dose chemotherapy with peripheral blood progenitor support in women with high-risk primary breast cancer. *Bone Marrow Transplantation*, *40*(3), 267–272. <https://doi.org/10.1038/sj.bmt.1705692>
- Vigushin, D. M., Ali, S., Pace, P. E., Mirsaidi, N., Ito, K., Adcock, I., & Coombes, R. C. (2001). Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*, *7*(4), 971–976.
- Waddington, C. H. (1957). *Strategy of the genes*. Place of publication not identified: Taylor & Francis.
- Waks, A. G., & Winer, E. P. (2019). Breast Cancer Treatment: A Review. *JAMA*, *321*(3), 288. <https://doi.org/10.1001/jama.2018.19323>
- Waldron, H. A. (1983). A brief history of scrotal cancer. *Occupational and Environmental Medicine*, *40*(4), 390–401. <https://doi.org/10.1136/oem.40.4.390>
- Wee, Z. N., Li, Z., Lee, P. L., Lee, S. T., Lim, Y. P., & Yu, Q. (2014). EZH2-Mediated Inactivation of IFN- γ -JAK-STAT1 Signaling Is an Effective Therapeutic Target in MYC-Driven Prostate Cancer. *Cell Reports*, *8*(1), 204–216. <https://doi.org/10.1016/j.celrep.2014.05.045>
- World Health Organization. (2018). Cancer today. Retrieved 7 January 2019, from International Agency for Research on Cancer website: <http://gco.iarc.fr/today/home>
- Wright, W. C. (1940). *Diseases of Workers*. Hafner Publishing Company.
- Xie, Z., Bi, C., Cheong, L. L., Liu, S. C., Huang, G., Zhou, J., ... Chng, W. J. (2011). Determinants of Sensitivity to DZNep Induced Apoptosis in Multiple Myeloma Cells. *PLoS ONE*, *6*(6), e21583. <https://doi.org/10.1371/journal.pone.0021583>
- Yan, J., Ng, S.-B., Tay, J. L.-S., Lin, B., Koh, T. L., Tan, J., ... Chng, W.-J. (2013). EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone

methyltransferase activity. *Blood*, 121(22), 4512–4520. <https://doi.org/10.1182/blood-2012-08-450494>

Zhang, C., Hou, D., Wei, H., Zhao, M., Yang, L., Liu, Q., ... Shao, C. (2016). Lack of interferon- γ receptor results in a microenvironment favorable for intestinal tumorigenesis. *Oncotarget*, 7(27). <https://doi.org/10.18632/oncotarget.9867>

Zhou, J., Bi, C., Cheong, L.-L., Mahara, S., Liu, S.-C., Tay, K.-G., ... Chng, W.-J. (2011). The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. *Blood*, 118(10), 2830–2839. <https://doi.org/10.1182/blood-2010-07-294827>